

7. Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. *Gut* 2019; 68:130–9. doi:10.1136/gutjnl-2017-314828.
8. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. [online]. 2021. [cit. 2021-08-29]. Available at: <https://seer.cancer.gov/statfacts/html/pancreas.html>.
9. Hernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. *World J Gastrointest Oncol* 2016; 8(1): 18–29. doi: <http://dx.doi.org/10.4251/wjgov.8.1.18>
10. Falasca M, Kim M, Casari I. Pancreatic cancer: Current research and future directions. *Biochim Biophys Acta* 2016; 1865(2):123–32. doi: 10.1016/j.bbcan.2016.01.001.
11. Gharibi A, Adamian Y, Kelber JA. Cellular and molecular aspects of pancreatic cancer. *Acta Histochem* 2016; 118(3):305–16. doi: 10.1016/j.acthis.2016.01.009.
12. Zhang X, Shi S, Zhang B, et al. Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. *Am J Cancer Res* 2018; 8(3):332–353.
13. Ryska M. Karcinom pankreatu – současný efektivní diagnostický a terapeutický postup. *Cas Lek Ces* 2016; 155:38–43.
14. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. *Gastroenterology* 2020; 159(1):358–362. doi: 10.1053/j.gastro.2020.03.088.
15. Owens DK, Davidson KW, Krist AH, et al. Screening for pancreatic cancer: US preventive services Task force reaffirmation recommendation statement. *JAMA* 2019; 322:438–44. doi:10.1001/jama.2019.10232.
16. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. *Gut* 2020; 69(1):7–17. doi: 10.1136/gutjnl-2019-319352.
17. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). *Ann Oncol* 2012; 23(7):1880–8. doi: 10.1093/annonc/mdr541.
18. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. *Langenbecks Arch Surg* 2008; 393(4):535–45. doi: 10.1007/s00423-007-0266-2.
19. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. *Lancet* 2020; 395(10242):2008–2020. doi: 10.1016/S0140-6736(20)30974-0.
20. Stolzenberg-Solomon RZ, Schairer C, Moore S, et al. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. *Am J Clin Nutr* 2013; 98(4):1057–65. doi: 10.3945/ajcn.113.058123.
21. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. *JAMA* 1995;273(20):1605–9.
22. Andersen DK, Korc M, Petersen GM, Eibl G, et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. *Diabetes* 2017; 66(5):1103–1110. doi: 10.2337/db16-1477.
23. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. *Lancet Public Health* 2019; 4(3):e137–e147. doi: 10.1016/S2468-2667(18)30267-6.
24. Rebourvs V, Gaujoux S, d'Assignies G, et al. Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). *Clin Cancer Res* 2015; 21(15):3522–8. doi: 10.1158/1078-0432.CCR-14-2385.
25. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 2004; 64(7):2634–8. doi: 10.1158/0008-5472.can-03-3823.
26. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. *Fam Cancer* 2011; 10(2):323–30. doi: 10.1007/s10689-010-9414-x.
27. Vanek P, Slodicka P, Zoundjiekpon V. Pancreatic cancer screening: ready for prime time?. *Gastroent Hepatol* 2021; 75(5):390–398. doi: 10.48095/ccgh2021390.
28. Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. *JAMA* 2021; 326(9):851–862. doi: 10.1001/jama.2021.13027.
29. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* 2018; 24(43):4846–4861. doi:10.3748/wjg.v24.i43.4846
30. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin* 2021; 71(1):7–33. doi: 10.3322/caac.21654.
31. Macdonald S, Macleod U, Campbell NC, et al. Systematic review of factors influencing patient and practitioner delay in diagnosis of upper gastrointestinal cancer. *Br J Cancer* 2006; 94(9):1272–80. doi: 10.1038/sj.bjc.6603089.
32. Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. *Lancet Gastroenterol Hepatol* 2016; 1(4):298–306. doi: 10.1016/S2468-1253(16)30079-6.
33. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in Primary Care: A Systematic Review. *Pancreas* 2016; 45(6):814–8. doi: 10.1097/MPA.0000000000000527.
34. Kunovsky L, Dite P, Jabandziev P, et al. Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis. *J Clin Med* 2021; 10(24):5779. doi: 10.3390/jcm10245779.
35. Sharma A, Smyrk TC, Levy MJ, et al. Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis. *Gastroenterology* 2018; 155(2): 490–500. doi: 10.1053/j.gastro.2018.04.025.
36. Sah RP, Sharma A, Nagpal S, et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. *Gastroenterology* 2019; 156(6): 1742–1752. doi: 10.1053/j.gastro.2019.01.039.
37. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; 26 Suppl 5:v56–68. doi: 10.1093/annonc/mdv295.
38. Lang J, Kunovsky L, Kala Z, Trna J. Risk factors of pancreatic cancer and their possible uses in diagnostics. *Neoplasma* 2021; 68(2):227–239. doi: 10.4149/neo_2020_200706N699.
39. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. *J Gastrointest Oncol* 2012; 3(2):105–19. doi: 10.3978/j.issn.2078-6891.2011.021.
40. Kaur S, Baine MJ, Jain M, et al. Early diagnosis of pancreatic cancer: Challenges and new developments. *Biomark Med* 2012; 6(5): 597–612. doi:10.2217/bmm.12.69.
41. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol* 2006; 24(33):5313–27. doi: 10.1200/JCO.2006.08.2644.
42. Kunovsky L, Tesarikova P, Kala Z, et al. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. *Can J Gastroenterol Hepatol* 2018; 2018:5389820. doi: 10.1155/2018/5389820.
43. Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. *J Gastroenterol Hepatol* 2004; 19(2):182–6. doi: 10.1111/j.1440-1746.2004.03219.x.
44. Eid M, Karousi P, Kunovsky L, et al. The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. *Biomedicines* 2021; 9(10):1468. doi: 10.3390/biomedicines9101468.
45. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. *J Am Coll Surg* 1999; 188(4):415–20. doi: 10.1016/s1072-7515(98)00326-3.
46. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. *Eur J Surg Oncol* 2007; 33(3):266–70. doi: 10.1016/j.ejso.2006.10.004.
47. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. *Eur J Surg Oncol* 2000; 26(5):474–9. doi: 10.1053/ejso.1999.0925.
48. Goggins M. Molecular markers of early pancreatic cancer. *J Clin Oncol*. 2005 Jul 10;23(20):4524–31. doi: 10.1200/JCO.2005.19.711.
49. Fahrman JF, Schmidt CM, Mao X, et al. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. *Gastroenterology* 2021; 160(4):1373–1383.e6. doi: 10.1053/j.gastro.2020.11.052.
50. Bauer TM, El-Rayes BF, Li X, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. *Cancer* 2013; 119(2):285–92. doi: 10.1002/cncr.27734.
51. Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. *HPB (Oxford)* 2014; 16(5):430–8. doi: 10.1111/hpb.12154.
52. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. *Pancreas* 2008; 37(3):269–74. doi: 10.1097/MPA.0b013e31816d8185.
53. Pelzer U, Hilbig A, Sinn M, et al. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. *Front Oncol* 2013; 3:155. doi: 10.3389/fonc.2013.00155.
54. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. *Ann Surg Oncol* 2013; 20(7):2188–96. doi: 10.1245/s10434-012-2809-1.
55. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. *Lancet* 2016; 388(10039):73–85. doi:10.1016/s0140-6736(16)00141-0
56. Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. *Technol Cancer Res Treat* 2020; 19. doi: 10.1177/1533033820962117.
57. Rawat M, Kadian K, Gupta Y, et al. MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. *Genes (Basel)* 2019; 10(10):752. doi: 10.3390/genes10100752.
58. Johansen JS, Calatayud D, Albieri V, et al. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. *Int J Cancer* 2016; 139(10):2312–24. doi: 10.1002/ijc.30291.
59. Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. *Int J Cancer* 2012; 131(3):683–691. doi:10.1002/ijc.26422
60. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. *JAMA* 2014; 311(4):392–404. doi:10.1001/jama.2013.284664
61. Shams R, Saberi S, Zali M, et al. Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods. *Sci Rep* 2020; 10(1):7559. doi: 10.1038/s41598-020-64569-1.
62. Iwagami Y, Eguchi H, Nagano H, et al. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. *Br J Cancer* 2013; 109(2):502–11. doi: 10.1038/bjc.2013.320.
63. Martini V, Timme-Bronsert S, Fichtner-Feigl S, et al. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. *Cancers* 2019; 11(11). doi:10.3390/cancers11111659.